A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

Phase 1

Completed

• Conditions: Pulmonary Disease, Chronic Obstructive

• Registration Number: NCT00163098
• Lead Sponsor: Pfizer

Brief Summary

A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD

Detailed Description

Not available

Study Timeline

• Study Start: 2004-12
• Study First Submitted: 2005-09-08
• Study First Submitted QC: 2005-09-11
• Study First Posted: 2005-09-13
• Study Completion: 2005-12
• Status Verified: 2006-10
• Last Update Submitted: 2006-10-12
• Last Update Posted: 2006-10-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 136

Inclusion Criteria

• GOLD criteria 2 to 4
• 10 pack year history of smoking

Exclusion Criteria

• Women of child bearing potential

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Effect on exercise tolerance

Secondary Outcome Measures

Name	Time	Method
Effect on lung function and quality of life

Trial Locations

Locations (1)

Pfizer Investigational Site